In breast screening programs, which set of metrics best describes program quality?

In breast screening programs, which set of metrics best describes program quality?

• A. Recall rate, cancer detection rate, and clinical outcome measures
• B. Recall rate, positive predictive value (PPV), cancer detection rate (CDR)
• C. Patient satisfaction and wait times
• D. Image storage capacity and equipment age

Answer: (B)

Focusing on how well a screening program performs in detecting cancers while keeping unnecessary follow-ups to a minimum is the key. Recall rate shows how often a screening result leads to additional testing, reflecting the balance between missing cancers and causing needless anxiety and procedures. Positive predictive value tells you how often a recalled case actually turns out to be cancer, which speaks to the efficiency and usefulness of recalls. Cancer detection rate measures how many cancers are found per number of screens, reflecting the program’s effectiveness in catching disease early. Together, these three metrics capture the core aspects of screening quality: sensitivity to cancer, specificity to avoid unnecessary recalls, and overall detection performance. Other options focus on patient experience, infrastructure, or long-term outcomes, which are important but do not describe the screening process’s quality as directly.

Focusing on how well a screening program performs in detecting cancers while keeping unnecessary follow-ups to a minimum is the key. Recall rate shows how often a screening result leads to additional testing, reflecting the balance between missing cancers and causing needless anxiety and procedures. Positive predictive value tells you how often a recalled case actually turns out to be cancer, which speaks to the efficiency and usefulness of recalls. Cancer detection rate measures how many cancers are found per number of screens, reflecting the program’s effectiveness in catching disease early. Together, these three metrics capture the core aspects of screening quality: sensitivity to cancer, specificity to avoid unnecessary recalls, and overall detection performance. Other options focus on patient experience, infrastructure, or long-term outcomes, which are important but do not describe the screening process’s quality as directly.